On July 21, GenFleet Therapeutics-B rose 5.76% in regular trading, trading at 38.2 HKD/share, with turnover of approximately HKD 26.46 million. The stock is staging a technical recovery above the placement price following completion of its new H-share offering.

The company completed the placement of 13.6 million new H-shares on July 17 at HKD 34.69 per share, representing a 9.71% discount to the pre-deal closing price. Net proceeds of approximately HKD 467 million will be used to advance clinical development of its RAS inhibitor pipeline, including GFH276, GFS202A, and GFS784. The stock fell 8.56% on the placement date but has since rebounded above the placement price. Notable institutional participation included Wellington Management Group LLP, which acquired approximately 1.4 million shares at the placement price.

The company's core pipeline GFH375, an oral KRAS G12D inhibitor, has received two Breakthrough Therapy Designations and is currently in a Phase III registrational trial for second-line pancreatic cancer, with multiple research presentations accepted at WCLC and ESMO conferences.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)